5302392025-01-012025-03-315302392025-03-315302392024-03-315302392024-04-012025-03-315302392025-01-012025-03-31in-capmkt:OtherExpenses1Member5302392025-01-012025-03-31in-capmkt:OtherExpenses2Member5302392024-04-012025-03-31in-capmkt:OtherExpenses1Member5302392024-04-012025-03-31in-capmkt:OtherExpenses2Member5302392025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25302392024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25302392025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares530239SUVENNOTLISTEDINE495B01038SUVEN LIFE SCIENCES LIMITEDMain BoardEquity2024-04-012025-03-312025-05-132025-05-06INRLakhsQuarterlyFourth quarterSingle segmentThe Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented2025-05-1311:00:002025-05-1312:15:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31UnauditedConsolidated14670000122250002689500000060661000013467000392216000466344000-4394490000-4394490000000-4394490000000-439449000-5698000-4451470002180740001-2.02-2.0200-2.02-2.021) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 13, 2025. The results for the year ended March 31, 2025 has been audited and for the quarter ended March 31, 2025 has been reviewed by our statutory auditors. <BR> 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <BR> 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc. <BR> 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. <BR> 5) The Company has allotted 7,26,91,239 equity shares amounting to Rs. 39,980.18 lakhs through rights issue on November 16, 2022. <BR> Summary of Utilisation of Proceeds of Rights issue <BR> Particulars Amount Rs. In lakhs <BR> Amount Raised through Rights Issue of Shares 39,980.18 <BR> Less: Rights Issue Expenses (280.00) <BR> Less: Amount Utilised (39,700.18) <BR> Balance Amount 0.00 <BR> 6) The Company implemented SLSL Employee Stock Option Scheme 2020 (ESOP) for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination and Remuneration Committee on May 6, 2024. For the period ended March 31, 2025, the employee benefit expense includes a charge of Rs.127.45 Lakhs in respect of equity-settled share-based payment transactions, in accordance with Ind AS 102 - Share-based Payment. <BR> 7) The figures for the current quarter and quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2025 and March 31, 2024, respectively and published year to date figures upto 3rd quarter ended 31st December 2024 and 31st December 2023, respectively, regrouped as necessary.2024-04-012025-03-31AuditedConsolidated665580001089690001755270000002082490004660005821700015160450001782977000-16074500000-16074500000000-16074500000000-1607450000-5833000-16132830002181740001881794000-7.37-7.3700-7.37-7.37R & D Expenses373250000Other Expenses18966000R & D Expenses1439618000Other Expenses764270005947190009700001808000004860004860005971100002375000222785000133640001502550002270080000760000614172000119000001262760007547230001351833000218074000881794000109986800010998680000017105000171050000384200048424000522660006028000582940001601610001640500023486000025196500013518330004660004710000-5050000-186010005205000000315850000944000053071000046400003645000690290000005682500012745000-497560000000060353000-1547097000000-60510000-15410460000000000003727580000000000000000000005682500001865473000154954000000000000007097000046600000-75630009310000931000149324000150255000Items that will not be reclassified to profit or loss-464000Items that will be reclassified to profit or loss-5234000-5698000Items that will not be reclassified to profit or loss-599000Items that will be reclassified to profit or loss-5234000-58330000000-5698000-5833000AuditedtrueKARVY & Co.true2024-10-31